Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care ApproachByApril 1st 1998
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?ByWilliam P. Castelli, MD,W. Virgil Brown, MD,Evan A. Stein, MD, PhD,James Shepherd, MD, PhDApril 1st 1998
Issues and Controversies in PharmacoeconomicsByWilliam F. McGhan, PharmD, PhD,James M. McKenney, PharmD,Susan Andrade, ScD,Sidney C. Smith, Jr, MD,Bruce Kinosian, MD,Joel W. Hay, PhDApril 1st 1998
Pharmacoeconomics Perspectives: Payers, Providers, and PatientsByPaul C. Langley, PhD,Nicolaas Otten, PharmD,Peter Davey, MD,James C. Bonnette, MD,J. Russell Teagarden,William F. McGhan, PharmD, PhDApril 1st 1998
Assessing the Value and Affordability of Cholesterol Reduction in the Managed Care SettingByEdgar R. Gonzalez, PharmD,Barbara S. Kannewurf, RPhApril 1st 1998
